Search
Multiple Sclerosis Paid Clinical Trials in Vermont
A listing of 1 Multiple Sclerosis clinical trials in Vermont actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 1 of 1
The state of Vermont currently has 1 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Burlington, Bennington, Berlin and White River Junction.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Atopic Dermatitis (Eczema) Study
Recruiting
Sign up for a clinical trial today and contribute to the advancement of medical research, paving the way for innovative treatments. Receive financial compensation for your participation and benefit from complimentary medical care.
Featured Trial
Primary Sclerosing Cholangitis (PSC) Study
Recruiting
Living with PSC can be difficult, but participating in a clinical trial can be a way to take an active role in your medical care via a potential new treatment.
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.
The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: The University of Vermont and State Agricultural College, Burlington, Vermont
Conditions: Multiple Sclerosis, Relapsing-Remitting
1 - 1 of 1